- Home
- IBG vs POAI Comparison
IBG vs POAI Comparison
Compare IBG & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- POAI
- Stock Information
- Founded
- IBG 2018
- POAI 2002
- Country
- IBG Australia
- POAI United States
- Employees
- IBG N/A
- POAI N/A
- Industry
- IBG Beverages (Production/Distribution)
- POAI Industrial Specialties
- Sector
- IBG Consumer Staples
- POAI Health Care
- Exchange
- IBG Nasdaq
- POAI Nasdaq
- Market Cap
- IBG 7.8M
- POAI 7.8M
- IPO Year
- IBG 2024
- POAI N/A
- Fundamental
- Price
- IBG $3.33
- POAI $14.77
- Analyst Decision
- IBG Strong Buy
- POAI Hold
- Analyst Count
- IBG 1
- POAI 1
- Target Price
- IBG N/A
- POAI N/A
- AVG Volume (30 Days)
- IBG 6.0M
- POAI 230.9K
- Earning Date
- IBG 11-15-2025
- POAI 11-11-2025
- Dividend Yield
- IBG N/A
- POAI N/A
- EPS Growth
- IBG N/A
- POAI N/A
- EPS
- IBG N/A
- POAI N/A
- Revenue
- IBG $2,931,243.00
- POAI $1,664,696.00
- Revenue This Year
- IBG N/A
- POAI $486.27
- Revenue Next Year
- IBG N/A
- POAI $65.50
- P/E Ratio
- IBG N/A
- POAI N/A
- Revenue Growth
- IBG N/A
- POAI 71.65
- 52 Week Low
- IBG $1.48
- POAI $8.25
- 52 Week High
- IBG $11.50
- POAI $45.90
- Technical
- Relative Strength Index (RSI)
- IBG 62.66
- POAI 78.34
- Support Level
- IBG $2.16
- POAI $12.15
- Resistance Level
- IBG $5.38
- POAI $15.15
- Average True Range (ATR)
- IBG 0.72
- POAI 1.98
- MACD
- IBG 0.10
- POAI 1.19
- Stochastic Oscillator
- IBG 48.70
- POAI 45.66
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.